Cryoport, Inc. (NASDAQ:CYRX) Given Average Recommendation of “Buy” by Brokerages

Cryoport, Inc. (NASDAQ:CYRXGet Rating) has been given a consensus recommendation of “Buy” by the eight analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $80.67.

CYRX has been the topic of several research analyst reports. B. Riley cut their price objective on Cryoport from $94.00 to $70.00 in a research report on Wednesday, March 2nd. TheStreet cut Cryoport from a “c-” rating to a “d+” rating in a research note on Friday, January 28th. Zacks Investment Research lowered Cryoport from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 10th. Roth Capital raised Cryoport from a “neutral” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Wednesday, January 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $45.00 price objective on shares of Cryoport in a report on Wednesday, April 13th.

NASDAQ CYRX traded up $0.66 during trading hours on Tuesday, reaching $30.59. The company’s stock had a trading volume of 7,978 shares, compared to its average volume of 571,637. The firm’s 50-day moving average price is $33.28 and its 200-day moving average price is $51.63. The company has a quick ratio of 15.88, a current ratio of 16.26 and a debt-to-equity ratio of 0.64. Cryoport has a 1 year low of $26.69 and a 1 year high of $86.30. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -5.19 and a beta of 1.07.

Cryoport (NASDAQ:CYRXGet Rating) last posted its quarterly earnings results on Thursday, February 24th. The consumer goods maker reported ($1.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($1.17). Cryoport had a negative return on equity of 12.00% and a negative net margin of 123.77%. The business had revenue of $56.44 million during the quarter, compared to analysts’ expectations of $57.61 million. During the same period in the prior year, the firm posted ($0.28) earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Equities research analysts anticipate that Cryoport will post -0.56 EPS for the current fiscal year.

In related news, CFO Robert Stefanovich sold 1,095 shares of Cryoport stock in a transaction on Wednesday, March 9th. The stock was sold at an average price of $31.05, for a total value of $33,999.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jerrell Shelton sold 3,298 shares of Cryoport stock in a transaction on Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total value of $102,402.90. The disclosure for this sale can be found here. Insiders sold 5,803 shares of company stock valued at $180,183 over the last ninety days. Insiders own 9.70% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Captrust Financial Advisors lifted its holdings in shares of Cryoport by 35.4% in the 3rd quarter. Captrust Financial Advisors now owns 624 shares of the consumer goods maker’s stock valued at $42,000 after purchasing an additional 163 shares during the last quarter. Pinebridge Investments L.P. acquired a new position in Cryoport in the 4th quarter valued at about $77,000. Lindbrook Capital LLC acquired a new position in Cryoport in the 4th quarter valued at about $87,000. FinTrust Capital Advisors LLC increased its position in Cryoport by 47.1% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 2,212 shares of the consumer goods maker’s stock valued at $147,000 after acquiring an additional 708 shares during the period. Finally, Parallel Advisors LLC acquired a new position in Cryoport in the 4th quarter valued at about $158,000.

Cryoport Company Profile (Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.

Further Reading

Analyst Recommendations for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.